ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- PMID: 21712404
- DOI: 10.1093/eurheartj/ehr158
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Abstract
Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies’ Task forces on CVD prevention in clinical practice.2 – 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.
Similar articles
-
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis. 2011 Jul;217 Suppl 1:S1-44. doi: 10.1016/j.atherosclerosis.2011.06.012. Atherosclerosis. 2011. PMID: 21723445 Review. No abstract available.
-
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis. 2011 Jul;217(1):3-46. doi: 10.1016/j.atherosclerosis.2011.06.028. Atherosclerosis. 2011. PMID: 21882396 Review. No abstract available.
-
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1. Atherosclerosis. 2016. PMID: 27594540 No abstract available.
-
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.Eur Heart J. 2014 Apr;35(15):960-8. doi: 10.1093/eurheartj/ehu107. Epub 2014 Mar 17. Eur Heart J. 2014. PMID: 24639424
-
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].Kardiol Pol. 2016;74(11):1234-1318. doi: 10.5603/KP.2016.0157. Kardiol Pol. 2016. PMID: 27910077 Polish. No abstract available.
Cited by
-
Analysis of correlative factors of female coronary slow-flow phenomenon: A retrospective study.Medicine (Baltimore). 2024 May 24;103(21):e38262. doi: 10.1097/MD.0000000000038262. Medicine (Baltimore). 2024. PMID: 38787982 Free PMC article.
-
Health benefits of bluefin tuna consumption: (Thunnus thynnus) as a case study.Front Nutr. 2024 Apr 2;11:1340121. doi: 10.3389/fnut.2024.1340121. eCollection 2024. Front Nutr. 2024. PMID: 38628271 Free PMC article. Review.
-
An Update on Dyslipidemia Management and Medications: A Review.Cureus. 2024 Mar 16;16(3):e56255. doi: 10.7759/cureus.56255. eCollection 2024 Mar. Cureus. 2024. PMID: 38623110 Free PMC article. Review.
-
Association of Circulating Endothelial Nitric Oxide Synthase Levels with Phosphataemia in Patients on Haemodialysis.Biomedicines. 2024 Mar 19;12(3):687. doi: 10.3390/biomedicines12030687. Biomedicines. 2024. PMID: 38540300 Free PMC article.
-
Addressing Knowledge Gaps in the Primary Prevention of Atherosclerotic Heart Disease.J Am Heart Assoc. 2024 Mar 19;13(6):e033991. doi: 10.1161/JAHA.123.033991. Epub 2024 Mar 8. J Am Heart Assoc. 2024. PMID: 38456421 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous